Goldman Sachs Group Boosts Smith & Nephew (SN) Price Target to GBX 1,440

Share on StockTwits

Smith & Nephew (LON:SN) had its price target boosted by Goldman Sachs Group from GBX 1,400 ($18.29) to GBX 1,440 ($18.82) in a research report released on Monday. Goldman Sachs Group currently has a neutral rating on the stock.

SN has been the topic of several other reports. Morgan Stanley upgraded Smith & Nephew to an overweight rating and increased their target price for the company from GBX 1,457 ($19.04) to GBX 1,692 ($22.11) in a research note on Monday, December 10th. BNP Paribas downgraded Smith & Nephew to a neutral rating and increased their target price for the company from GBX 1,475 ($19.27) to GBX 1,525 ($19.93) in a research note on Friday, February 8th. JPMorgan Chase & Co. reiterated a neutral rating and set a GBX 1,477 ($19.30) target price on shares of Smith & Nephew in a research note on Tuesday, January 8th. UBS Group increased their target price on Smith & Nephew from GBX 1,340 ($17.51) to GBX 1,390 ($18.16) and gave the company a neutral rating in a research note on Monday, January 28th. Finally, Deutsche Bank reiterated a hold rating on shares of Smith & Nephew in a research note on Friday, February 8th. Nine equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of GBX 1,479.36 ($19.33).

Shares of SN opened at GBX 1,475.50 ($19.28) on Monday. Smith & Nephew has a 12 month low of GBX 1,173 ($15.33) and a 12 month high of GBX 1,442 ($18.84).

The firm also recently announced a dividend, which will be paid on Wednesday, May 8th. Shareholders of record on Thursday, April 4th will be paid a dividend of $0.22 per share. This represents a yield of 1.1%. This is an increase from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date is Thursday, April 4th.

About Smith & Nephew

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

See Also: What are the benefits of a balanced fund?

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.

Leave a Reply